Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection

International Journal of Infectious Diseases

Volumn 17, Issue 10, 2013, Pages

  Bon, Isabella ^a   Clò, Alberto ^a   Borderi, Marco ^a   Colangeli, Vincenzo ^a   Calza, Leonardo ^a   Morini, Silvia ^a   Miserocchi, Anna ^a   Cricca, Monica ^a   Gibellini, Davide ^a   Re, Maria Carla ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Genotyping test; HIV; Maraviroc; Trofile ; Tropism

Indexed keywords

ABACAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

ADULT; AGED; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; GENOTYPE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHYLOGENY; VIRAL TROPISM; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

GENOTYPING TEST; HIV; MARAVIROC; TROFILE™; TROPISM;

ADULT; AGED; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RECEPTORS, CCR5; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD; VIRAL TROPISM; VIRUS REPLICATION; YOUNG ADULT;

EID: 84883818095     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.02.020     Document Type: Article

References (61)

1. Berger E.A., Murphy P., Farber J.M. Chemokine receptors as HIV coreceptors: roles in viral entry, tropism, and disease. Ann Rev Immunol 1999, 17:657-700.
2. Zhang C., Xu S., Wei J., Guo H. Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: implications for the future usage of CCR5 antagonists and AIDS vaccine development. Int J Infect Dis 2009, 13:e212-e216.
3. Clementi M., Lazzarin A. Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance. Clin Microbiol Infect 2010, 16:1532-1538.
4. Wilen C.B., Tilton J.C., Doms R.W. Molecular mechanisms of HIV entry. Adv Exp Med Biol 2012, 726:223-242.
5. Åsjö B., Morfeldt-Manson L., Albert J., Biberfeld G., Karlsson A., Lidman K., et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986, 2:660-662.
6. Rübsamen-Waigmann H., Becker W.B., Helm E.B., Brodt R., Fischer H., Henco K., et al. Isolation of variants of lymphocytopathic retroviruses from the peripheral blood and cerebral spinal fluid of patients with ARC or AIDS. J Med Virol 1986, 19:335-344.
7. Shioda T., Levy J.A., Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991, 349:167-169.
8. Kozak S.L., Platt E.J., Madani N., Ferro J., Peden F.E., Kabat D. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 1997, 71:873-882.
9. Jensen M.A., Li F.S., van't Wout A.B., Nickle D.C., Shriner D., He H.X., et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003, 77:13376-13388.
10. Poveda E., Paredes R., Moreno S., Alcamí J., Córdoba J., Delgado R., et al. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. AIDS Rev 2012, 14:208-217.
11. Philpott S.M. HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 2003, 1:217-227.
12. Koot M., Keet I.P., Vos A.H., de Goede R.E., Roos M.T., Coutinho R.A., et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.
13. Koot M., Van Leeuwen R., De Goede R.E., Keet I.P., Danner S., Eeftinck Schattenkerk J.K., et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999, 179:254-258.
14. Shankarappa R., Margolick J.B., Gange S.J., Rodrigo A.G., Upchurch D., Farzadegan H., et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999, 73:10489-10502.
15. Waters L., Mandalia S., Randell P., Wildfire A., Gazzard B., Moyle G. The impact of HIV tropism on decrease in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008, 46:1617-1623.
16. Regoes R.R., Bonhoeffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 2005, 13:269-277.
17. Huang W., Eshleman S.H., Toma J., Fransen S., Stawiski E., Paxinos E.E., et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007, 81:7885-7893.
18. Dimonte S., Mercurio F., Svicher V., D'Arrigo R., Perno C.F., Ceccherini-Silberstein F. Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v3 signatures in the regulation of co-receptor usage. Retrovirology 2011, 8:33-44.
19. Equils O., Garratty E., Wei L.S., Plaeger S., Tapia M., Deville J., et al. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. J Infect Dis 2000, 182:751-757.
20. Philpott S., Weiser B., Anastos K., Kitchen C.M., Robison E., Meyer W.A., et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001, 107:431-438.
21. Skrabal K., Trouplin V., Labrosse B., Obry V., Damond F., Hance A.J., et al. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 2003, 11:809-814.
22. Jiao Y., Wang P., Zhang H., Zhang T., Zhang Y., Zhu H., et al. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?. Immunol Invest 2011, 40:597-613.
23. Johnston E.R., Zijenah L.S., Mutetwa S., Kantor R., Kittinunvorakoon C., Katzenstein D.A. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003, 77:7682-7688.
24. Delobel P., Sandres-Sauné K., Cazabat M., Pasquier C., Marchou B., Massip P., et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005, 38:382-392.
25. Whitcomb J.M., Huang W., Fransen S., Limoli K., Toma J., Wrin T., et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007, 51:566-575.
26. Raymond S., Delobel P., Mavigner M., Cazabat M., Souyris C., Sandres-Sauné Cuzin L., et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008, 22:F11-F16.
27. Svicher V., D'Arrigo R., Alteri C., Andreoni M., Angarano G., Antinori A., et al. Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol 2010, 33:195-206.
28. Shephard D.A. The 1975 Declaration of Helsinki and consent. Can Med Assoc J 1976, 115:1191-1192.
29. Perfetto S.P., McCrary G. Immunophenotyping and assessment of cell function by three-color flow cytometry of peripheral blood lymphocytes. HIV protocols 1999, 397-407. Humana Press, Totowa NJ. N. Michael, J.H. Kim (Eds.).
30. Vandekerckhove L.P., Wensing A.M., Kaiser R., Brun-Vézinet F., Clotet B., De Luca A., et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011, 11:394-407.
31. Svicher V., Alteri C., Montano M., D'Arrigo R., Andreoni M., Angarano G., et al. Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol 2012, 35:17-25.
32. Vandekerckhove L., Verhofstede C., Demecheleer E., De Wit S., Florence E., Fransen K., et al. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. J Antimicrob Chemother 2011, 66:265-272.
33. Petropoulos C, Limoli K, Whitcomb J. Validation studies defining the performance of Monogram's HIV coreceptor tropism assay. Abstract 57. Abstracts of the Fifth European HIV Drug Resistance Workshop, Cascais, Portugal, 2007.
34. Saag M., Heera J., Goodrich J. Reanalysis of the MERIT study with the enhanced Trofile assay (MERIT-ES). Abstract H-1232a. Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008 2008, American Society for Microbiology, Washington, DC.
35. Brumme Z.L., Dong W.W., Yip B., Wynhoven B., Hoffman N.G., Swanstrom R., et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004, 18:F1-F9.
36. Lin N.H., Kuritzkes D.R. Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS 2009, 4:481-487.
37. Symons J., Vandekerckhove L., Paredes R., Verhofstede C., Bellido R., Demecheleer E., et al. Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice. Clin Microbiol Infect 2012, 8:606-612.
38. Moyle G.J., Wildfire A., Mandalia S., Mayer H., Goodrich J., Whitcomb J., et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005, 191:866-872.
39. Hunt P.W., Harrigan P.R., Huang W., Bates M., Williamson D.W., McCune J.M., et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006, 194:926-930.
40. Melby T., Despirito M., Demasi R., Heilek-Snyder G., Greenberg M.L., Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006, 194:238-246.
41. Poveda E., Briz V., Roulet V., del Mar Gonzalez M., Faudon J.L., Soriano V. Correlation between a phenotypic assay and 3 bioinformatic tools for determining HIV co-receptor use. AIDS 2007, 21:1487-1490.
42. Wilkin T.J., Su Z., Kuritzkes D.R., Hughes M., Flexner C., Gross R., et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007, 44:591-595.
43. Poveda E., Alcamí J., Paredes R., Córdoba J., Gutiérrez F., Llibre J.M., et al. Genotypic determination of HIV tropism-clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 2010, 12:135-148.
44. Parczewski M., Leszczyszyn-Pynka M., Urbanska A., Bander D., Boron-Kaczmarska A. Genotypic tropism of antiretroviral-treated patients with drug resistant HIV-1. J Med Virol 2011, 83:1869-1875.
45. Delgado E., Fernández-García A., Vega Y., Cuevas T., Pinilla M., García V., et al. Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes. J Antimicrob Chemother 2012, 67:25-31.
46. Monno L., Saracino A., Scudeller L., Punzi G., Brindicci G., Altamura M., et al. Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B. Antimicrob Agents Chemother 2011, 55:5078-5084.
47. Pastore C., Nedellec R., Ramos A., Pontow S., Ratner L., Mosier D.E. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006, 80:750-758.
48. Suphaphiphat P., Essex M., Lee T.H. Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of HIV type 1 gp120 interaction with the CCR5 coreceptor. Virology 2007, 360:182-190.
49. Garrido C., Roulet V., Chueca N., Poveda E., Aguilera A., Skrabal K., et al. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008, 46:887-891.
50. Seclén E., Garrido C., del Mar Gonzalez M., Gonzalez-Lahoz J., de Mendoza C., Soriano V., et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 2010, 65:1486-1492.
51. Trabaud M.A., Icard V., Scholtes C., Perpoint T., Koffi J., Cotte L., et al. Discordance in HIV-1 co-receptor use prediction by different genotypic algorithms and phenotype assay: intermediate profile in relation to concordant predictions. J Med Virol 2012, 84:402-413.
52. Loftin L.M., Kienzle M., Yi Y., Lee B., Lee F.H., Gray L., et al. Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficacy of ENV-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry. Virology 2010, 402:135-148.
53. Toma J., Whitcomb J.M., Petropoulos C.J., Huang W. Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors. AIDS 2010, 24:2181-2186.
54. Svicher V., Balestra E., Cento V., Sarmati L., Dori L., Vandenbroucke I., et al. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res 2011, 90:42-53.
55. Sierra S., Kaiser R., Lübke N., Thielen A., Schuelter E., Heger E., et al. Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach. J Vis Exp 2011, (58). pii: 3264.
56. Santoro M.M., Armenia D., Fabeni L., Santoro M., Gori C., Forbici F., et al. The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. Clin Microbiol Infect 2012, 18:289-299.
57. Symons J., van Lelyveld S.F., Hoepelman A.I., van Ham P.M., de Jong D., Wensing A.M., et al. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. J Antimicrob Chemother 2011, 66:890-895.
58. Reuter S., Braken P., Jensen B., Sierra-Aragon S., Oette M., Balduin M., et al. Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice. Eur J Med Res 2010, 15:231-237.
59. Fatkenheuer G., Nelson M., Lazzarin A., Konourina I., Hoepelman A.I., Lampiris H., et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359:1442-1455.
60. Hicks C.B., Cahn P., Cooper D.A., Walmsley S.L., Katlama C., Clotet B., et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006, 368:466-475.
61. Steigbigel R.T., Cooper D.A., Kumar P.N., Eron J.E., Schechter M., Markowitz M., et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359:339-354.